Resultado de búsqueda
Ver el perfil de Thomas Breuer, MD, MSc en LinkedIn, una red profesional de más de 1.000 millones de miembros. Leading the GSK Global Health organisation, a team of more than 200 outstanding...
3 de jul. de 2014 · Chief #GlobalHealth Officer. @GSK. Focused on improving #HealthEquity by getting ahead of infectious diseases in LIC through GH R&D & Access to GSK products. Medical & Health Spain gsk.com/en-gb/responsi… Joined July 2014. 247 Following. 263 Followers. Tweets & replies. Media. Likes. Thomas Breuer, MD, MSc (Epidemiology) @ThomasBreuer_MD. ·.
23 de jun. de 2022 · Thomas Breuer, GSK Chief Global Health Officer, speaking at the Kigali Summit on Malaria and NTDs in Rwanda, said: “I am delighted to renew our commitment to global health research for the coming decade, consistent with our purpose to unite our science, technology, and talent to get ahead of disease together and our ambition to ...
3 de oct. de 2018 · During the pandemic, safety data available to GSK and the company’s analyses of those data were shared regularly with the authorities through weekly teleconferences and monthly written periodic safety update reports.
But immunisations are often overlooked in the AMR conversation, according to Thomas Breuer, chief global health officer at one of the world’s largest vaccine developers, GSK.
Thomas Breuer. Chief medical officer of GSK Vaccines, GSK, 20, Avenue Fleming, Building W23, 1300 Wavre, Belgium. Rino Rappuoli
Thomas Breuer, MD, MSc. Senior Vice President Head of Global Vaccines Development GSK Biologicals. Vaccines business characteristics. Few global players and high barriers to entry. Complex manufacturing. Large scale investment. Long product life cycles. – Complex intellectual property. High probability of R&D success. – 70% post-POC.
